$105 Million is the total value of BML Capital Management, LLC's 25 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ANF | New | ABERCROMBIE & FITCH COcl a | $13,084,290 | – | 571,117 | +100.0% | 12.50% | – |
| IMRA | New | IMARA INC | $12,342,696 | – | 3,017,774 | +100.0% | 11.79% | – |
| TLYS | New | TILLYS INCcl a | $10,451,338 | – | 1,154,844 | +100.0% | 9.98% | – |
| New | DISC MEDICINE INC | $9,945,000 | – | 500,000 | +100.0% | 9.50% | – | |
| BIL | New | SPDR SER TRbloomberg 1-3 mo | $9,147,000 | – | 100,000 | +100.0% | 8.74% | – |
| New | PARDES BIOSCIENCES INC | $8,226,893 | – | 4,867,984 | +100.0% | 7.86% | – | |
| New | ELIEM THERAPEUTICS INC | $6,698,242 | – | 1,825,134 | +100.0% | 6.40% | – | |
| STSA | New | SATSUMA PHARMACEUTICALS INC | $5,796,000 | – | 6,440,000 | +100.0% | 5.54% | – |
| SESN | New | SESEN BIO INC | $5,014,947 | – | 8,227,969 | +100.0% | 4.79% | – |
| ADVM | New | ADVERUM BIOTECHNOLOGIES INC | $4,095,430 | – | 7,067,179 | +100.0% | 3.91% | – |
| VRCA | New | VERRICA PHARMACEUTICALS INC | $3,054,164 | – | 1,110,605 | +100.0% | 2.92% | – |
| MTCR | New | METACRINE INC | $2,762,404 | – | 6,167,458 | +100.0% | 2.64% | – |
| ATHA | New | ATHIRA PHARMA INC | $2,265,799 | – | 714,763 | +100.0% | 2.16% | – |
| New | ASTROTECH CORP | $2,201,896 | – | 220,410 | +100.0% | 2.10% | – | |
| ABIO | New | ARCA BIOPHARMA INC | $2,034,067 | – | 858,256 | +100.0% | 1.94% | – |
| RELL | New | RICHARDSON ELECTRS LTD | $2,034,007 | – | 95,359 | +100.0% | 1.94% | – |
| FBRX | New | FORTE BIOSCIENCES INC | $1,461,364 | – | 1,461,364 | +100.0% | 1.40% | – |
| RVP | New | RETRACTABLE TECHNOLOGIES INC | $1,096,530 | – | 668,575 | +100.0% | 1.05% | – |
| MIST | New | MILESTONE PHARMACEUTICALS IN | $712,800 | – | 180,000 | +100.0% | 0.68% | – |
| GRAY | New | GRAYBUG VISION INC | $617,972 | – | 1,235,943 | +100.0% | 0.59% | – |
| New | LISATA THERAPEUTICS INC | $616,913 | – | 243,839 | +100.0% | 0.59% | – | |
| PASG | New | PASSAGE BIO INC | $465,704 | – | 337,467 | +100.0% | 0.44% | – |
| ACET | New | ADICET BIO INC | $268,200 | – | 30,000 | +100.0% | 0.26% | – |
| SPRB | New | SPRUCE BIOSCIENCES INC | $243,436 | – | 221,830 | +100.0% | 0.23% | – |
| ELEV | New | ELEVATION ONCOLOGY INC | $37,965 | – | 39,963 | +100.0% | 0.04% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SPDR SER TR | 4 | Q3 2023 | 16.9% |
| ADVERUM BIOTECHNOLOGIES INC | 4 | Q3 2023 | 7.4% |
| ELIEM THERAPEUTICS INC | 4 | Q3 2023 | 6.4% |
| ATHIRA PHARMA INC | 4 | Q3 2023 | 4.9% |
| ASTROTECH CORP | 4 | Q3 2023 | 2.8% |
| ARCA BIOPHARMA INC | 4 | Q3 2023 | 1.9% |
| FORTE BIOSCIENCES INC | 4 | Q3 2023 | 1.6% |
| VERRICA PHARMACEUTICALS INC | 4 | Q3 2023 | 2.9% |
| PASSAGE BIO INC | 4 | Q3 2023 | 1.7% |
| RETRACTABLE TECHNOLOGIES INC | 4 | Q3 2023 | 1.0% |
View BML Capital Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR/A | 2024-04-24 |
| 13F-HR | 2024-04-23 |
| 13F-HR/A | 2024-02-02 |
| 13F-HR | 2024-01-30 |
| 13F-HR | 2023-10-23 |
| 13F-HR | 2023-07-24 |
| 13F-HR | 2023-04-14 |
| 13F-HR | 2023-02-13 |
View BML Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.